AstraZeneca faces longer delay on key cancer drug testKey data on whether an AstraZeneca drug improves overall survival for people with non-small cell lung cancer that has spread in the body will not now be released until the second half of the year, the Financial Times reported on Monday. (APMHE 57251)
Kisqali, Keytruda backed for NHS use in ScotlandThe Scottish Medicines Consortium has recommended use of Novartis's Kisqali (ribociclib) for advanced breast cancer in postmenopausal women and Merck & Co's Keytruda (pembrolizumab) for advanced Hodgkin’s lymphoma in patients who have failed to respond to previous treatments, The Times said on Tuesday.
Epilepsy drug sees 1,300% price increase in IrelandEssential Pharma increased the price of an epilepsy medicine by more than 1,300% and sought price rises of up to 3,000% to maintain other drugs in the Irish market, The Times said on Tuesday.
Theranos founder charged with ‘massive’ securities fraudThe FT on Thursday reported that Elizabeth Holmes, the Theranos founder who was once feted as the future of Silicon Valley, has been stripped of control of her blood-testing group and banned from public companies for 10 years after U.S. authorities charged her with “massive” securities fraud.
Hikma’s generic version of GSK’s Advair delayedThe launch of Hikma’s generic version of GlaxoSmithKline’s blockbuster respiratory drug Advair is delayed in the U.S. after the Food and Drug Administration insisted the company conduct a further clinical study following a dispute process, The Times said on Monday.
Former GSK CEO Witty gets new healthcare role in U.S.The FT on Tuesday covered the appointment of former GSK CEO Sir Andrew Witty to head UnitedHealth Group’s Optum division, which offers services including pharmacy benefit management in the U.S. (APMHE 57279).
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.